Skip to main content
Erschienen in: Molecular Neurodegeneration 1/2013

Open Access 01.09.2013 | Poster presentation

Development of a paradigm to investigate mechanisms of divided and selective attention impairment in the rodent models of Alzheimer’s disease

verfasst von: Gytis Baranauskas, Natasa Svirskiene, Gytis Svirskis

Erschienen in: Molecular Neurodegeneration | Sonderheft 1/2013

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
In Alzheimer’s disease impaired attention can be detected almost immediately after the first signs of memory loss and is considered to be a major cause of difficulties in the patients everyday life in the early stages of Alzheimer’s disease. Several types of attention are recognized such as divided, selective and sustained attention. Selective and divided attention are impaired most in the Alzheimer’s disease patients while sustained attention remains relatively intact. However, most attention tests in animal models of Alzheimer’s disease such as the five-choice serial reaction time task evaluates sustained but not other attention types. We decided to profit from a recent finding that Alzheimer’s patients have an impaired ability to detect objects approaching on a collision course in tests for selective and divided visual attention [1, 2]. Collision detection is conserved across species and is performed by specialized collision-sensitive neurons in the superior colliculus of both in humans and rodents facilitating extension to humans of the results obtained in animals.
However, so far little is known about collision-sensitive neurons in rats and mice and such a visual stimulus has not been used in attention tasks in rodents. To establish a paradigm for selective and divided visual attention tests in rodents, we recorded collision sensitive neurons in the rat superior colliculus by employing tetrode extracellular recordings in male, >1 month old rats. Collision sensitive neurons in the superficial layers of the superior colliculus were identified by their ability to respond to stimuli imitating collision but not to the ones veering slightly off. Collision sensitive neurons responded well to both dark (a black image on a white background) and bright (a bright image on a dark background) stimuli. Most putative collision-sensitive neurons could be assigned to eta class. Importantly, responses of collision-sensitive neurons were highly dependent on contrast, a parameter to be used to evaluate divided attention by presenting two different collision stimuli of different contrast. We will use these tests to investigate the effects of a 2-week intracerebroventricular infusion of beta-amyloid-(1-42), a rat model of Alzheimer’s disease [3], on divided and selective attention. This work was supported by a Lithuanian Research Council grant Nr. VP1-3.1-SMM-08-K-01-022.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Fritelli C, Borghetti D, ludice G, et al: Effects of Alzheimer’s disease and mild cognitive impairment on drving ability: a controlled clinical study by simulated driving test. Int J Geriatr Psychiatry. 2009, 24: 232-238. 10.1002/gps.2095.CrossRef Fritelli C, Borghetti D, ludice G, et al: Effects of Alzheimer’s disease and mild cognitive impairment on drving ability: a controlled clinical study by simulated driving test. Int J Geriatr Psychiatry. 2009, 24: 232-238. 10.1002/gps.2095.CrossRef
2.
Zurück zum Zitat Uc EY, Rizzo M, Anderson SW, et al: Unsafe rear-end collision avoidance in Alzheimer’s disease. J Neurol Sci. 2006, 251: 35-43. 10.1016/j.jns.2006.08.011.CrossRefPubMed Uc EY, Rizzo M, Anderson SW, et al: Unsafe rear-end collision avoidance in Alzheimer’s disease. J Neurol Sci. 2006, 251: 35-43. 10.1016/j.jns.2006.08.011.CrossRefPubMed
3.
Zurück zum Zitat Nabeshima T: Trial to produce animal model of Alzheimer’s disease by continuous infusion of beta-amyloid protein into the rat cerebral ventricle. Nihon Shinkei Seishin Yakurikagu Zasshi. 1995, 15: 411-418. Nabeshima T: Trial to produce animal model of Alzheimer’s disease by continuous infusion of beta-amyloid protein into the rat cerebral ventricle. Nihon Shinkei Seishin Yakurikagu Zasshi. 1995, 15: 411-418.
Metadaten
Titel
Development of a paradigm to investigate mechanisms of divided and selective attention impairment in the rodent models of Alzheimer’s disease
verfasst von
Gytis Baranauskas
Natasa Svirskiene
Gytis Svirskis
Publikationsdatum
01.09.2013
Verlag
BioMed Central
Erschienen in
Molecular Neurodegeneration / Ausgabe Sonderheft 1/2013
Elektronische ISSN: 1750-1326
DOI
https://doi.org/10.1186/1750-1326-8-S1-P6

Weitere Artikel der Sonderheft 1/2013

Molecular Neurodegeneration 1/2013 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.